NCT04431895

Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

A Prospective,Single-center,Single-Arm,Single-Blind Pilot Study To Investigate The Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a 6 month study that will evaluate the efficacy of 5mg tofacitinib tablet taken twice a day in patients with refractory myasthenia gravis. Twenty adult participants will receive a four month treatment of tofacitinib followed by elution for one month.

Conditions

• Myasthenia Gravis, Generalized

Interventions

Type	Name	Description
DRUG	Tofacitinib 5 MG	tofacitinib 5 mg tablet administered twice a day for 6 months

Timeline

• Start date: 2020-06-11
• Primary completion: 2024-03-21
• Completion: 2024-03-31
• First posted: 2020-06-16
• Last updated: 2025-09-16

Locations

1 site across 1 country: China